BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: Results of a prospective randomized study using modified treatment schemes

International Urology and Nephrology

Volumn 28, Issue 4, 1996, Pages 499-509

  Melekos, M D ^a   Zarakovitis, I ^a   Dandinis, K ^a   Fokaefs, E ^a   Chionis, H ^a   Dauaher, H ^b   Barbalias, G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; EPIRUBICIN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL CANCER;

EID: 0030482263     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02550957     Document Type: Article

References (34)

1. Herr, H. W., Laudone, V. P., Whitmore, W. F. Jr.: An overview of intravesical therapy for superficial bladder tumors. J. Urol., 138, 1363 (1987).
2. Martinez-Pineiro, J. A., Jimenez-Leon, J. S., Martinez-Pineiro, L. Jr., Fiter, L., Mosteiro, J. A., Navarro, J., Garcia Matres, M. J., Cárcamo, P.: Intravesical therapy comparing BCG, adriamycin and thiotepa in 200 patients with superficial bladder cancer: A randomized prospective study. In: F. M. J. Debruyne, L. Denis, A. P. M. van der Meijden (eds): BCG in Superficial Bladder Cancer. Alan R. Liss Inc., New York 1989, pp. 237-252.
3. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A. Jr., Sullivan, J., Sarosdy, M. F., Crissman, J. D., Coltman, C. A.: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder. N. Engl. J. Med., 325, 1205 (1991).
4. Lamm, D. L.: BCG in perspective: Advances in the treatment of superficial bladder cancer. Eur. Urol., 27 (Suppl. 1), 2 (1995).
5. Ganzina, F.: 4'-epi-doxorubicin, a new analogue of doxorubicin: Preliminary overview of preclinical and clinical data. Cancer Treat. Rev., 10, 1 (1993).
6. Cersonimo, R. L., Hong, W. K.: Epirubicin: A review of the pharmacology, clinical activity and adverse effects of an adriamycin analogue. J. Clin. Oncol., 4, 425 (1986).
7. Matsumura, Y., Tsushima, T., Ozaki, Y., Yoshimoto, J., Akagi, T., Obama, T., Nasu, Y., Ohmori, H.: Intravesical chemotherapy with 4'-epi-adriamycin in patients with superficial bladder tumors. Cancer Chemother. Pharmacol., 16, 176 (1986).
8. Kurth, K. H., Vijgh, W. J. V., ten Kate, F., Bogdanowitz, J. F., Carpenter, P. J., van Reyswoud, I.: Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. J. Urol., 146, 1508 (1991).
9. Calais da Silva, F., Ferrito, F., Brandao, T., Santos, A.: 4'-epi-doxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer. Eur. Urol., 21, 42 (1992).
10. Melekos, M. D., Dauaher, H., Fokaefs, E., Barbalias, G.: Intravesical instillations of 4'-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: Results of a controlled prospective study. J. Urol., 147, 371 (1992).
11. Melekos, M. D., Chionis, H., Paranychianakis, G., Dauaher, H.: Intravesical 4'-epidoxorubicin (epirubicin) versus bacillus Calmette-Guérin: A controlled prospective study on the prophylaxis of superficial bladder cancer. Cancer, 72, 1749 (1993).
12. 1 papillary carcinoma of the bladder. J. Urol., 149, 749 (1993).
13. Melekos, M. D.: Prophylaxis of superficial bladder cancer with a modified intravesical epirubicin treatment schedule. Oncology, 50, 40 (1993).
14. Cutler, S. J., Ederer, F.: Maximum utilization of the life-table method in analyzing survival. J. Chron. Dis., 8, 699 (1958).
15. Zincke, H., Utz, D. C., Taylor, W. F., Myers, R. P., Leary, F. J.: Influence of thiotepa and doxorubicin instillations at time of transurethral surgical treatment of bladder cancer on tumor recurrence: A prospective, randomized, double-blind, controlled trial. J. Urol., 129, 505 (1983).
16. Soloway, M. S., Jordan, A. M., Murphy, W. M.: Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. In: F. M. J. Debruyne, L. Denis, A. P. M. van der Meijden (eds): BCG in Superficial Bladder Cancer. Alan R. Liss Inc., New York 1989, pp. 215-236.
17. Lamm, D. L., Griffith, J. D.: The place of intravesical chemotherapy as defined by the results of prospective randomized studies (substances and treatment schemes). In: Recent Progress in Bladder and Kidney Cancer. Wiley-Liss Inc., New York 1992, pp. 43-53.
18. Bouffioux, Ch., Kurth, K. H., Bono, A., Oosterlinck, W., Boecken Kruger, C., de Pauw, M., Sylvester, R. and Members of the EORTC Genitourinary Group: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of 2 EORTC randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J. Urol., 153, 934 (1995).
19. Page, B. H., Levison, V. B., Curwen, M. P.: The site of recurrence of noninfiltrating bladder tumors. Br. J. Urol., 50, 237 (1978).
20. Badalament, R. A., Herr, H. W., Wong, G. Y., Gnecco, C., Pinsky, C. M., Whitmore, W. F. Jr., Fair, W. R., Oettgen, H. F.: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J. Clin. Oncol., 5, 441 (1987).
21. Hudson, M. A., Ratliff, T. L., Gillen, D. P., Haaff, E. O., Dresner, S. M., Catalona, W. J.: Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: A prospective randomized trial. J. Urol., 138, 295 (1987).
22. Catalona, W. J., Hudson, M. A., Gillen, D. P., Andriole, G. L., Ratliff, T. L.: Risks and benefits of repeated course of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J. Urol., 137, 220 (1987).
23. Ratliff, T. L., Catalona, W. J.: Depressed proliferative responses in patients treated with 12 weeks of intravesical BCG. J. Urol., 144, 230 A (Abstract 144), Part 2 (1989).
24. Morales, A.: Long-term results and complications of intracavitary BCG therapy for bladder cancer. J. Urol., 132, 457 (1984).
25. Herr, H. W., Laudone, V. P., Badalament, R. A:, Oettgen, H. F., Sogani, P. L., Freedman, B. D., Melamed, M. R., Whitmore, W. F. Jr.: BCG therapy alters the progression of superficial bladder cancer, J. Clin. Oncol., 6, 1450 (1988).
26. Coplen, D. E., Marcus, M. D., Myers, J. A., Ratliff, T. L., Catalona, W. J.: Long-term follow-up of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guérin: Analysis of possible predictions of response free of tumor. J. Urol., 144, 652 (1990).
27. Melekos, M. D., Pantazakos, A., Markou, S., Skopa, G., Athanassopoulos, A., Barbalias, G.: Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer. Int. Urol. Nephrol., 22, 433 (1990).
28. Melekos, M. D.: Intravesical bacillus Calmette-Guérin prophylactic treatment for superficial bladder tumors: Results of a controlled prospective study. Urol. Int., 45, 137 (1990).
29. Brosman, S. A.: Bacillus Calmette-Guérin immunotherapy. Urol. Clin. N. Amer., 19, 557 (1992).
30. Melekos, M. D., Chionis, H., Pantazakos, A., Fokaefs, E., Paranychianakis, G., Dauaher, H.: Intravesical bacillus Calmette-Guérin immunoprophylaxis of superficial bladder cancer: Results of a controlled prospective trial with a modified treatment schedule. J. Urol., 149, 744 (1993).
31. Nadler, R. B., Catalona, W. J., Hudsoin, M. A., Ratliff, T. L.: Durability of the tumor-free response for intravesical bacillus Calmette-Guérin therapy. J. Urol., 152, 367 (1994).
32. Soloway, M. S., Perry, A.: Bacillus Calmette-Guérin for the treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C. J. Urol., 137, 871 (1987).
33. Herr, H. W., Badalament, R. A., Amato, D. A., Laudone, V. P., Fair, W. R., Whitmore, W. F. Jr.: Superficial bladder cancer treated with bacillus Calmette-Guérin: A multivariable analysis of factors affecting tumor progression. J. Urol., 141, 22 (1989).
34. Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D., Garbeghlio, A.: A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: Is it effective? J. Urol., 146, 32 (1991).